Abatacept: A Potential Culprit for Mitral Valve Calcification?

Abstract

Get full access to this article

View all access options for this article.

References

Sendaydiego

Gold

Dubreuil

, et al. Comparative safety of biologic and targeted synthetic disease-modifying anti-rheumatic drugs for cardiovascular outcomes in rheumatoid arthritis. Rheumatology. 2025; 64:3434-3443. doi:10.1093/rheumatology/keaf096

Urena

Kikoïne

Guerrero

Mitral annular calcification: understanding the disease and treatment options. Struct Heart. 2025; 9: 100668. doi:10.1016/j.shj.2025.100668

Naranjo

Busto

Sellers

, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981; 30: 239-245. doi:10.1038/clpt.1981.154

Axmann

Herman

Zaiss

, et al. CTLA-4 directly inhibits osteoclast formation. Ann Rheum Dis. 2008; 67: 1603-1609. doi:10.1136/ard.2007.080713

Okada

Kajiya

Omata

, et al. CTLA4-Ig directly inhibits osteoclastogenesis by interfering with intracellular calcium oscillations in bone marrow macrophages. J Bone Miner Res. 2019; 34: 1744-1752. doi:10.1002/jbmr.3754

Sukumaran

Vijayan

Abatacept in the treatment of juvenile dermatomyositis-associated calcifications in a 16-year-old girl. Case Rep Rheumatol. 2020; 2020: 4073879. doi:10.1155/2020/4073879